Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05380557 · ClinicalTrials.gov registry record
ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing
A clinical trial, sponsored by Invitae Corporation.
- Terminated
- Registry status
- 2
- Enrollment target
NCT05380557: Clinical Trial study, sponsored by Invitae Corporation.
NCT05380557 is a clinical trial that was terminated before completion, run by Invitae Corporation. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05380557 was terminated before completion, sponsored by Invitae Corporation.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study includes participants with pancreatic cancer who are undergoing genetic testing at Invitae related to their diagnosis of pancreatic cancer. Our goal in this study is two-fold. First, we would like to research whether any inherited changes in genes may be associated with pancreatic cancer. Second, we would like to learn more about patient experiences with genetic testing, such as patient understanding of the testing, health-related actions taken (or planned to take) as a result of testing, communication and action of family members based on test results, and psychological impact of testing. This research study involves allowing collection of tumor tissue (from a prior biopsy and/or surgery), a blood sample, and sending surveys to participants for their opinion on the impact of the genetic testing as well as clinicians for relevant baseline and medical history information.
Interventions
- DIAGNOSTIC_TEST Germline genetic testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2022-09-06 |
Why NCT05380557 stopped before completion
NCT05380557 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Germline genetic testing is the first listed.
NCT05380557 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05380557 about?
NCT05380557 is a clinical study titled "ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing". This study includes participants with pancreatic cancer who are undergoing genetic testing at Invitae related to their diagnosis of pancreatic cancer. Our goal in this study is two-fold. First, we would like to research whether any inherited changes in genes may be associated with pancreatic cancer...
What is the current status of trial NCT05380557?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2021-08-23. Estimated completion is 2022-09-06.
What interventions are being tested in trial NCT05380557?
The interventions under investigation include: Germline genetic testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05380557?
This trial is sponsored by Invitae Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI